VEA
PGNX

Virtus ETF Advisers’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Virtus ETF Advisers’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-71,758
Closed -$273K – 494
2020
Q1 		$273K Sell
71,758
-10,475
-13% -$45.1K 0.11% 237
2019
Q4 		$419K Buy
82,233
+20,460
+33% +$108K 0.07% 242
2019
Q3 		$312K Sell
61,773
-3,441
-5% -$17.2K 0.06% 195
2019
Q2 		$402K Buy
+65,214
New +$314K 0.08% 191
2019
Q1 		– Sell
-64,532
Closed -$271K – 296
2018
Q4 		$271K Buy
64,532
+12,534
+24% +$63.8K 0.05% 147
2018
Q3 		$326K Sell
51,998
-38,179
-42% -$293K 0.03% 182
2018
Q2 		$725K Buy
+90,177
New +$688K 0.64% 88
2017
Q4 		– Sell
-148,929
Closed -$1.1M – 287
2017
Q3 		$1.1M Hold
148,929
– – 0.15% 55
2017
Q2 		$1.01M Buy
148,929
+33,629
+29% +$248K 0.15% 65
2017
Q1 		$1.09M Buy
115,300
+11,087
+11% +$111K 0.19% 60
2016
Q4 		$900K Sell
104,213
-31,127
-23% -$230K 0.27% 71
2016
Q3 		$857K Buy
135,340
+17,055
+14% +$103K 0.41% 38
2016
Q2 		$499K Buy
118,285
+14,478
+14% +$69.9K 0.37% 59
2016
Q1 		$453K Hold
103,807
– – 0.62% 45
2015
Q4 		$636K Buy
+103,807
New +$681K 1.75% 15

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Virtus ETF Advisers's PGNX Position: Q2 2020 in Review

Virtus ETF Advisers sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 71,758 shares — an estimated $273K sold.

Virtus ETF Advisers first reported a position in PGNX in Q4 2015 and held it in 15 quarters. The position peaked at $1.1M in Q3 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Virtus ETF Advisers reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Virtus ETF Advisers sold 71,758 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $273K.
  • Virtus ETF Advisers first reported a position in Progenics Pharmaceuticals Inc in Q4 2015 and held it in 15 quarters.
  • Virtus ETF Advisers's Progenics Pharmaceuticals Inc position peaked at $1.1M in Q3 2017.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Virtus ETF Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.